Eiger BioPharmaceuticals stock enters final liquidation phase

Eiger BioPharmaceuticals stock is now linked to a post-confirmation liquidation estate, while four court-supervised asset sales generated USD 87.3 million in gross proceeds. ElevenFlo reported on September 19, 2026, that claims reconciliation was continuing after the plan became effective.

Claims deadline passed in September

The liquidating trustee faced a claims objection deadline of September 18, 2026, at 5:00 p.m. Central Time, following an extension in a September 1 court order. That date places the estate in an administrative phase rather than an operating pharmaceutical business.

The distinction matters for former holders. The plan became effective on September 30, 2024, and cancelled the common stock, according to ElevenFlo. The same report says the existing equity interests were cancelled and discharged with a stated recovery of 0 percent, followed by later trust distributions.

Asset sales exceeded estate claims

The reported USD 87.3 million in gross proceeds came from four asset sales and was sufficient to pay secured and unsecured claims with interest. For investors, the key comparison is between the cancelled equity class at 0 percent under the plan and the subsequent cash distributions made through the liquidating trust.

As of the first quarter of 2026, the lead debtor's post-confirmation reports showed USD 13.56 million in total disbursements. That included USD 5.75 million of an anticipated USD 6.74 million in equity distributions, while general unsecured distributions reached USD 3.29 million of USD 3.76 million.

Historical Nasdaq listing

The EIGR ticker remains associated with Eiger BioPharmaceuticals in historical market references, but the company situation is defined by liquidation milestones rather than operating results. The September 30, 2024 effective date is therefore the central reference point for interpreting the former listing.